Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.
Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.
Evaluation of the TcBuster transposon system delivered by electroporation as a non-viral engineering approach for CAR T-cell generation
AMIRAN, VAHID
2025/2026
Abstract
Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.| File | Dimensione | Formato | |
|---|---|---|---|
|
Amiran_Vahid.pdf
Accesso riservato
Dimensione
3.09 MB
Formato
Adobe PDF
|
3.09 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/115432